Kilitch Drugs (India) Q4 FY24 Share Price & Earnings Call Analysis
- Market cap
- ₹705 Cr
- P/E
- 23.48
- ROE
- 10.59%
- PEG
- 0.62
- Price to sales
- 2.98
- Debt to equity
- 0.32
- 52W high / low
- ₹389 / ₹124
- Sales growth (5Y)
- 28.05%
- EBITDA margin
- 15.29%
- Net profit margin
- 10.55%
- Promoter holding
- 63.77%
- Sales (last year)
- ₹237 Cr
Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products[1]
Guidance scorecard · Q4 FY24 call
What Kilitch Drugs (India) Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
RevenueQ4 FY24 call
20–40%- Expecting 20%-25% growth in sales for FY 2025 over FY 2024.
- Overall year-on-year growth forecasted at approximately 25%-30% for FY 2025.
- Export market expected to contribute around 60%-65% of revenue, domestic market around 30%-40%.
- New facility designed considering client demand, especially near Mumbai for better QA audits and logistics.
2 more points from Kilitch Drugs (India) Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ4 FY24 call
Up 0–2%See what Kilitch Drugs (India) Ltd said on margins — free account, 30 seconds.
CapexQ4 FY24 call
Planned- Kilitch Drugs is investing around INR 100 crores to develop a new greenfield pharmaceutical project at Khopoli, Maharashtra, India.
- The building construction at the Mumbai plant has started; they expect to complete the first floor slab by end of the current month.
- Validation and production commencement is planned by May 25, 2024, in phased manner (Phase 1, 2, 3).
- Capex of around INR 50 crores was incurred for the Ethiopian facility till 2021, with production starting in 2021.
2 more points from Kilitch Drugs (India) Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ4 FY24 call
See what Kilitch Drugs (India) Ltd said on fundraising — free account, 30 seconds.
Order bookQ4 FY24 call
Rising- Kilitch Drugs has secured a significant government tender in Ethiopia worth USD 9.13 million, which will commence execution from Q2 FY24.
- The company expects this government order to trigger around 60% utilization of their Ethiopian facility capacity for the whole year.
- The facility is expected to run more efficiently and potentially add 20%-30% more orders beyond the government tender.
- For 2025, the new Khopoli plant validation starts May 25, with planned capacity: 260 million oral tablets, 31 million injectable vials, 47 million injectable ampoules annually.
- Demand near Mumbai is driven by client requirements for closer logistics and QA audits, indicating existing and new clients will supply from Khopoli in 2025.
2 more points from Kilitch Drugs (India) Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Kilitch Drugs (India) Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Kilitch Drugs (India) Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Kilitch Drugs (India) Ltd
Shareholding breakup across reporting periods.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 69.23% | 69.23% | 69.23% | 69.23% | 69.23% | 69.23% | 69.23% | 63.77% | 63.77% | 63.77% | 63.77% | 63.77% |
| FIIs + | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.12% | 0.10% |
| DIIs + | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.50% |
| Public + | 30.76% | 30.77% | 30.77% | 30.77% | 30.76% | 30.77% | 30.77% | 36.22% | 36.23% | 36.22% | 36.11% | 35.62% |
| No. of Shareholders | 9,062 | 9,525 | 9,620 | 9,920 | 10,139 | 9,749 | 10,379 | 10,929 | 12,043 | 11,785 | 12,627 | 12,319 |
Financials of Kilitch Drugs (India) Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 36.56 | 41.20 | 31.79 | 44.82 | 33.45 | 47.47 | 56.17 | 61.23 | 43.14 | 48.92 | 53.81 | 89.60 | 44.88 |
| Expenses + | 30.38 | 32.58 | 29.51 | 37.74 | 31.79 | 41.37 | 47.44 | 46.64 | 39.88 | 43.88 | 47.66 | 67.46 | 41.94 |
| Operating Profit | 6.18 | 8.62 | 2.28 | 7.08 | 1.66 | 6.10 | 8.73 | 14.59 | 3.26 | 5.04 | 6.15 | 22.14 | 2.94 |
| OPM % | 16.90% | 20.92% | 7.17% | 15.80% | 4.96% | 12.85% | 15.54% | 23.83% | 7.56% | 10.30% | 11.43% | 24.71% | 6.55% |
| Other Income + | 0.56 | 0.49 | 2.96 | 0.47 | 2.57 | 5.16 | 1.73 | 1.70 | 2.56 | 6.66 | 1.53 | 0.49 | 2.90 |
| Interest | 1.50 | 1.51 | 1.60 | 1.32 | 1.73 | 0.31 | 1.40 | 1.60 | 1.53 | 1.44 | 1.15 | 1.44 | 0.88 |
| Depreciation | 0.71 | 0.82 | 0.81 | 0.93 | 0.85 | 0.61 | 0.81 | 0.85 | 0.84 | 0.86 | 0.94 | 0.98 | 1.09 |
| Profit before tax | 4.53 | 6.78 | 2.83 | 5.30 | 1.65 | 10.34 | 8.25 | 13.84 | 3.45 | 9.40 | 5.59 | 20.21 | 3.87 |
| Tax % | 32.67% | 24.93% | 38.16% | 30.57% | 93.33% | 16.73% | 32.00% | 26.23% | 34.49% | 14.47% | 22.90% | 26.37% | 48.84% |
| Net Profit + | 3.06 | 5.09 | 1.74 | 3.68 | 0.11 | 8.61 | 5.61 | 10.22 | 2.27 | 8.04 | 4.31 | 14.88 | 1.96 |
| EPS in Rs | 0.99 | 1.35 | 0.83 | 1.03 | 0.38 | 2.46 | 1.70 | 2.97 | 0.87 | 2.34 | 1.27 | 4.15 | 0.83 |
Financials of Kilitch Drugs (India) Ltd
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 19 | 21 | 27 | 51 | 82 | 53 | 68 | 114 | 140 | 154 | 198 | 235 | 237 |
| Expenses + | 21 | 25 | 28 | 45 | 75 | 53 | 63 | 104 | 122 | 130 | 167 | 198 | 201 |
| Operating Profit | -2 | -4 | -1 | 6 | 7 | 0 | 5 | 10 | 18 | 24 | 32 | 37 | 36 |
| OPM % | -9% | -19% | -2.0% | 11% | 9% | 0.8% | 8% | 9% | 13% | 16% | 16% | 16% | 15% |
| Other Income + | 3 | 2 | 1 | 3 | 4 | 4 | 3 | 3 | 3 | 4 | 11 | 11 | 12 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 5 | 6 | 5 | 6 | 5 |
| Depreciation | 2 | 10 | 10 | 2 | 2 | 2 | 2 | 2 | 4 | 3 | 3 | 4 | 4 |
| Profit before tax | -1 | -12 | -9 | 6 | 9 | 2 | 5 | 10 | 12 | 19 | 34 | 39 | 39 |
| Tax % | -70% | -4% | -5% | 16% | 55% | 48% | 27% | 35% | 31% | 30% | 28% | 24% | |
| Net Profit + | -0 | -11 | -9 | 5 | 4 | 1 | 4 | 6 | 8 | 14 | 25 | 30 | 29 |
| EPS in Rs | -0.10 | -3.89 | -3.09 | 1.72 | 1.15 | 0.25 | 1.09 | 2.17 | 3.08 | 4.17 | 7.63 | 8.63 | 8.59 |
| Dividend Payout % | 0% | 0% | 0% | 13% | 20% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Kilitch Drugs (India) Ltd
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 14 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 35 |
| Reserves | 107 | 95 | 88 | 98 | 106 | 103 | 112 | 124 | 136 | 160 | 186 | 245 |
| Borrowings + | 0 | 0 | 1 | 1 | 9 | 13 | 15 | 20 | 22 | 32 | 49 | 89 |
| Other Liabilities + | 7 | 8 | 11 | 15 | 13 | 12 | 61 | 50 | 46 | 32 | 61 | 89 |
| Total Liabilities | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 | 458 |
| Fixed Assets + | 9 | 42 | 33 | 33 | 32 | 32 | 30 | 65 | 64 | 62 | 64 | 67 |
| CWIP | 0 | 0 | 1 | 3 | 20 | 30 | 65 | 3 | 4 | 6 | 47 | 140 |
| Investments | 72 | 49 | 53 | 56 | 53 | 52 | 60 | 71 | 62 | 72 | 72 | 75 |
| Other Assets + | 46 | 25 | 26 | 35 | 38 | 30 | 47 | 71 | 90 | 100 | 129 | 176 |
| Total Assets | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 | 458 |
Financials of Kilitch Drugs (India) Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -8 | 17 | 1 | 1 | 0 | 4 | 46 | 6 | 3 | -2 | 18 | 24 |
| Cash from Investing Activity + | -31 | -20 | -2 | -4 | -14 | -10 | -38 | -15 | 8 | -8 | -40 | -100 |
| Cash from Financing Activity + | -0 | 0 | -0 | 6 | 17 | 1 | 2 | 7 | -1 | 9 | 13 | 82 |
| Net Cash Flow | -39 | -2 | -0 | 2 | 3 | -5 | 10 | -2 | 10 | -1 | -9 | 6 |
| Free Cash Flow | -10 | -26 | -0 | -2 | -19 | -6 | 9 | -2 | -1 | -8 | -29 | -76 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 430% | -442% | -202% | 25% | 60% | 1,598% | 877% | 79% | 39% | 23% | 82% | 92% |
Financials of Kilitch Drugs (India) Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 243 | 286 | 196 | 148 | 86 | 109 | 122 | 132 | 142 | 149 | 156 | 186 |
| Inventory Days | 124 | 110 | 84 | 39 | 36 | 70 | 35 | 28 | 10 | 18 | 53 | 33 |
| Days Payable | 124 | 154 | 184 | 108 | 33 | 89 | 525 | 239 | 200 | 118 | 189 | 230 |
| Cash Conversion Cycle | 243 | 241 | 96 | 79 | 89 | 89 | -367 | -79 | -48 | 50 | 20 | -11 |
| Working Capital Days | 197 | 234 | 115 | 93 | 37 | 22 | -223 | -40 | -4 | 30 | 56 | 49 |
| ROCE % | -10% | -9% | 5% | 6% | 1% | 3% | 6% | 10% | 13% | 16% | 13% |
Guidance history
How Kilitch Drugs (India) Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q4 FY24 call → | 20–40% | Up 0–2% | Planned | — | Rising |
| Q4 FY23 call → | 20–40% | Up 0–2% | Planned | Planned | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
86 out of 100 — Strengthening
Over the past year its share price has done better than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | +23.7% | 76% |
| Last 6 months | +70.6% | 94% |
| Last 3 months | +26.5% | 91% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Kilitch Drugs (India) Ltd: 0.4 × 76 + 0.4 × 94 + 0.2 × 91 = 86.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 16 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Kilitch Drugs (India) Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Accretion Pharmaceuticals Ltd (Q2 FY27)
25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Sigachi Industries Ltd (Q2 FY27)
Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation
- Advanced Enzyme Technologies Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym
- IOL Chemicals (Q2 FY27)
Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL